These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 22212900)

  • 21. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery.
    Yun Y; Cho YW; Park K
    Adv Drug Deliv Rev; 2013 Jun; 65(6):822-32. PubMed ID: 23123292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of mucoadhesive polymeric nanoparticulate systems on oral bioavailability of a macromolecular model drug.
    Fabiano A; Piras AM; Uccello-Barretta G; Balzano F; Cesari A; Testai L; Citi V; Zambito Y
    Eur J Pharm Biopharm; 2018 Sep; 130():281-289. PubMed ID: 30006244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current approaches in lipid-based nanocarriers for oral drug delivery.
    Plaza-Oliver M; Santander-Ortega MJ; Lozano MV
    Drug Deliv Transl Res; 2021 Apr; 11(2):471-497. PubMed ID: 33528830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs.
    Wang XQ; Zhang Q
    Eur J Pharm Biopharm; 2012 Oct; 82(2):219-29. PubMed ID: 22885229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems.
    Sarparanta MP; Bimbo LM; Mäkilä EM; Salonen JJ; Laaksonen PH; Helariutta AM; Linder MB; Hirvonen JT; Laaksonen TJ; Santos HA; Airaksinen AJ
    Biomaterials; 2012 Apr; 33(11):3353-62. PubMed ID: 22285465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities.
    Jiang X; Wang N; Liu C; Zhuo Y; Liang L; Gan Y; Yu M
    Drug Discov Today; 2023 Apr; 28(4):103507. PubMed ID: 36690175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative study of Pluronic(®) F127-modified liposomes and chitosan-modified liposomes for mucus penetration and oral absorption of cyclosporine A in rats.
    Chen D; Xia D; Li X; Zhu Q; Yu H; Zhu C; Gan Y
    Int J Pharm; 2013 Jun; 449(1-2):1-9. PubMed ID: 23583840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanocarrier systems for oral drug delivery: do we really need them?
    Bernkop-Schnürch A
    Eur J Pharm Sci; 2013 May; 49(2):272-7. PubMed ID: 23537503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral delivery of proteins by biodegradable nanoparticles.
    Bakhru SH; Furtado S; Morello AP; Mathiowitz E
    Adv Drug Deliv Rev; 2013 Jun; 65(6):811-21. PubMed ID: 23608641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucus as a barrier to drug delivery – understanding and mimicking the barrier properties.
    Boegh M; Nielsen HM
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):179-86. PubMed ID: 25349046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel.
    Shi LL; Lu J; Cao Y; Liu JY; Zhang XX; Zhang H; Cui JH; Cao QR
    Drug Dev Ind Pharm; 2017 May; 43(5):839-846. PubMed ID: 27487431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of mesoporous silica nanoparticles for oral drug delivery - current status and perspective of MSNs drug carriers.
    Florek J; Caillard R; Kleitz F
    Nanoscale; 2017 Oct; 9(40):15252-15277. PubMed ID: 28984885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Systematic Review of Functionalized Polymeric Nanoparticles to Improve Intestinal Permeability of Drugs and Biological Products.
    de Souza ML; de Albuquerque Wanderley Sales V; Alves LP; Dos Santos WM; de Moura Ferraz LR; de Andrade Lima GS; Dos Santos Mendes LM; Rolim LA; Neto PJR
    Curr Pharm Des; 2022; 28(5):410-426. PubMed ID: 34348618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autonomous Untethered Microinjectors for Gastrointestinal Delivery of Insulin.
    Ghosh A; Liu W; Li L; Pahapale GJ; Choi SY; Xu L; Huang Q; Zhang R; Zhong Z; Selaru FM; Gracias DH
    ACS Nano; 2022 Oct; 16(10):16211-16220. PubMed ID: 36201302
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering strategies to enhance nanoparticle-mediated oral delivery.
    Yamanaka YJ; Leong KW
    J Biomater Sci Polym Ed; 2008; 19(12):1549-70. PubMed ID: 19017470
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multifunctional matrices for oral peptide delivery.
    Bernkop-Schnürch A; Walker G
    Crit Rev Ther Drug Carrier Syst; 2001; 18(5):459-501. PubMed ID: 11763498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs.
    Managuli RS; Raut SY; Reddy MS; Mutalik S
    Expert Opin Drug Deliv; 2018 Aug; 15(8):787-804. PubMed ID: 30025212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered nanoparticulate drug delivery systems: the next frontier for oral administration?
    Diab R; Jaafar-Maalej C; Fessi H; Maincent P
    AAPS J; 2012 Dec; 14(4):688-702. PubMed ID: 22767270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems.
    Chater PI; Wilcox MD; Pearson JP
    Adv Drug Deliv Rev; 2018 Jan; 124():184-192. PubMed ID: 29247764
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polymeric particulates to improve oral bioavailability of peptide drugs.
    Delie F; Blanco-Príeto MJ
    Molecules; 2005 Jan; 10(1):65-80. PubMed ID: 18007277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.